These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 19723036)
1. Is there a role for nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand resistance? Plantivaux A; Szegezdi E; Samali A; Egan L Ann N Y Acad Sci; 2009 Aug; 1171():38-49. PubMed ID: 19723036 [TBL] [Abstract][Full Text] [Related]
2. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022 [TBL] [Abstract][Full Text] [Related]
3. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition. Morales JC; Ruiz-Magaña MJ; Ruiz-Ruiz C Mol Immunol; 2007 Apr; 44(10):2587-97. PubMed ID: 17257681 [TBL] [Abstract][Full Text] [Related]
4. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells. Morello S; Sorrentino R; Porta A; Forte G; Popolo A; Petrella A; Pinto A J Cell Physiol; 2009 Nov; 221(2):378-86. PubMed ID: 19562684 [TBL] [Abstract][Full Text] [Related]
5. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Wang X; Ju W; Renouard J; Aden J; Belinsky SA; Lin Y Cancer Res; 2006 Jan; 66(2):1089-95. PubMed ID: 16424045 [TBL] [Abstract][Full Text] [Related]
6. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand. Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830 [TBL] [Abstract][Full Text] [Related]
7. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Braeuer SJ; Büneker C; Mohr A; Zwacka RM Mol Cancer Res; 2006 Oct; 4(10):715-28. PubMed ID: 17050666 [TBL] [Abstract][Full Text] [Related]
9. TRAIL as a target in anti-cancer therapy. Wu GS Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078 [TBL] [Abstract][Full Text] [Related]
10. [Chinese medicine Extractum trametes robiniophila murr augment tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in human hepatic cancer cell lines]. Chen XP; He SQ; Zhao X; Huang ZY; Li CH Zhonghua Wai Ke Za Zhi; 2005 Dec; 43(23):1524-7. PubMed ID: 16412290 [TBL] [Abstract][Full Text] [Related]
11. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). Ashkenazi A; Holland P; Eckhardt SG J Clin Oncol; 2008 Jul; 26(21):3621-30. PubMed ID: 18640940 [TBL] [Abstract][Full Text] [Related]
12. Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells. Deng LL; Shao YX; Lv HF; Deng HB; Lv FZ Neoplasma; 2012; 59(1):18-29. PubMed ID: 22017589 [TBL] [Abstract][Full Text] [Related]
13. Is TRAIL the holy grail of cancer therapy? Newsom-Davis T; Prieske S; Walczak H Apoptosis; 2009 Apr; 14(4):607-23. PubMed ID: 19194800 [TBL] [Abstract][Full Text] [Related]
14. [Recent advances for research on anti-tumor effects of TNF-related apoptosis-inducing ligand]. Yao GH; Hou YY Wei Sheng Yan Jiu; 2006 Jan; 35(1):115-7. PubMed ID: 16598953 [TBL] [Abstract][Full Text] [Related]
15. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462 [TBL] [Abstract][Full Text] [Related]
16. TRAIL and cancer therapy. Kruyt FA Cancer Lett; 2008 May; 263(1):14-25. PubMed ID: 18329793 [TBL] [Abstract][Full Text] [Related]
17. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Lee TJ; Um HJ; Min do S; Park JW; Choi KS; Kwon TK Free Radic Biol Med; 2009 Jun; 46(12):1639-49. PubMed ID: 19345731 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Goda AE; Yoshida T; Horinaka M; Yasuda T; Shiraishi T; Wakada M; Sakai T Oncogene; 2008 May; 27(24):3435-45. PubMed ID: 18193086 [TBL] [Abstract][Full Text] [Related]